Molecular Insight of Regorafenib Treatment for Colorectal Cancer

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Comprehensive molecular profiling of lung adenocarcinoma

The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732 · see citing works

Tumorigenesis and the angiogenic switch

Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559 · cited 1× · see citing works

Integrated Genomic Characterization of Papillary Thyroid Carcinoma

Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,080 · see citing works

Bevacizumab in Combination with Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955 · see citing works

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · see citing works

Fibroblast growth factor signalling: from development to cancer

Turner, N., & Grose, R. (2010) · Nature Reviews. Cancer · doi:10.1038/nrc2780 · Cited by 2,689 · see citing works

Liquid Biopsies: Genotyping Circulating Tumor DNA

Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210 · see citing works

Molecular Basis of Colorectal Cancer

Markowitz, S. D., & Bertagnolli, M. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804588 · Cited by 2,052 · see citing works

FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial

Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740 · see citing works

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621 · see citing works

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, É., Elisei, R., Jarząb, B., Vasselli, J. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,556 · see citing works

Tumor angiogenesis and vascular normalization: alternative therapeutic targets

Viallard, C., & Larrivée, B. (2017) · Angiogenesis · doi:10.1007/s10456-017-9562-9 · Cited by 1,435 · see citing works

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients with Metastatic Colorectal Cancer Previously Treated with an Oxaliplatin-Based Regimen

Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402 · see citing works

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355 · see citing works

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179 · see citing works

Continuation of Bevacizumab after First Progression in Metastatic Colorectal Cancer (ML18147): A Randomised Phase 3 Trial

Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166 · see citing works

Rational design of inhibitors that bind to inactive kinase conformations

Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,096 · see citing works

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., Cortesi, E., Tomasello, G., Ronzoni, M., Spadi, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403108 · Cited by 1,062 · see citing works

The landscape of kinase fusions in cancer

Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968 · see citing works

Ramucirumab versus Placebo in Combination with Second-Line FOLFIRI in Patients with Metastatic Colorectal Carcinoma That Progressed during or after First-Line Therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine (RAISE): A Randomised, Double-Blind, Multicentre, Phase 3 Study

Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952 · see citing works

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).

Fukuoka, S., Hara, H., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03296 · Cited by 890 · see citing works

Regorafenib plus Best Supportive Care versus Placebo plus Best Supportive Care in Asian Patients with Previously Treated Metastatic Colorectal Cancer (CONCUR): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

Li, J., Qin, S., Xu, R., Yau, T. C. C., Ma, B., Pan, H., Xu, J., Bai, Y., Chi, Y., Wang, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70156-7 · Cited by 813 · see citing works

Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels

Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., Mol, M. D., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 780 · see citing works

Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival <i>in vivo</i>

Lobov, I. B., Brooks, P. C., & Lang, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172161899 · Cited by 676 · cited 1× · see citing works

Therapeutic targeting of the angiopoietin–TIE pathway

Saharinen, P., Eklund, L., & Alitalo, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.278 · Cited by 620 · see citing works

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582 · see citing works

Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology

Akwii, R. G., Sajib, M. S., Zahra, F. T., & Mikelis, C. M. (2019) · Cells · doi:10.3390/cells8050471 · Cited by 552 · see citing works

Hypoxia and Vascular Endothelial Growth Factor Selectively Up-regulate Angiopoietin-2 in Bovine Microvascular Endothelial Cells

Oh, H., Takagi, H., Suzuma, K., Otani, A., Matsumura, M., & Honda, Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.22.15732 · Cited by 499 · see citing works

The Intersection between Tumor Angiogenesis and Immune Suppression

Rahma, O. E., & Hodi, F. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1543 · Cited by 480 · see citing works

Angiopoietin-1 Prevents VEGF-Induced Endothelial Permeability by Sequestering Src through mDia

Gavard, J., Patel, V., & Gutkind, J. S. (2008) · Developmental Cell · doi:10.1016/j.devcel.2007.10.019 · Cited by 409 · see citing works

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes

Drilon, A. E. D. C., Hu, Z. I., Lai, G. G. Y., & Tan, D. S. W. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.175 · Cited by 409 · see citing works

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

Ebos, J. M. L., Lee, C. R., Christensen, J. G., Mutsaers, A. J., & Kerbel, R. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708148104 · Cited by 368 · see citing works

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525360113 · Cited by 357 · see citing works

Vascular Permeability and Drug Delivery in Cancers

Azzi, S., Hebda, J. K., & Gavard, J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00211 · Cited by 352 · see citing works

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

Tabernero, J. M., Lenz, H., Siena, S., Sobrero, A. F., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00138-2 · Cited by 328 · see citing works

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

Bekaii‐Saab, T., Ou, F., Ahn, D. H., Boland, P. M., Ciombor, K. K., Heying, E. N., Dockter, T., Jacobs, N. L., Pasche, B., Cleary, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30272-4 · Cited by 287 · see citing works

Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model

Abou‐Elkacem, L., Arns, S., Brix, G., Gremse, F., Zopf, D., Kiessling, F. M., & Lederle, W. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1162 · Cited by 283 · see citing works

Tie1 controls angiopoietin function in vascular remodeling and inflammation

Korhonen, E. A., Lampinen, A., Giri, H., Anisimov, A., Kim, M., Allen, B., Fang, S., D’Amico, G., Sipilä, T. J., Lohela, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84923 · Cited by 283 · see citing works

The Complex Role of Angiopoietin-2 in the Angiopoietin-Tie Signaling PathwayPreprint

Thurston, G., & Daly, C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006650 · Cited by 267 · see citing works

Identification of a cKit(+) colonic crypt base secretory cell that supports Lgr5(+) stem cells in mice

Rothenberg, M. E., Nusse, Y., Kalisky, T., Lee, J. J., Dalerba, P., Scheeren, F., Lobo, N., Kulkarni, S., Sim, S., Qian, D., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.006 · Cited by 263 · see citing works

Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy

Ellis, L. M., & Hicklin, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5287 · Cited by 257 · see citing works

Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy

Zhao, P., Wang, Y., Kang, X., Wu, A., Yin, W., Tang, Y., Wang, J., Zhang, M., Duan, Y., & Huang, Y. (2018) · Chemical Science · doi:10.1039/c7sc04853j · Cited by 249 · see citing works

Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade

Rigamonti, N., Kadioglu, E., Keklikoglou, I., Wyser Rmili, C., Leow, C. C., & De Palma, M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.059 · Cited by 247 · see citing works

Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation

Kim, M., Allen, B. M., Korhonen, E. A., Nitschké, M., Yang, H. W., Bałuk, P., Saharinen, P., Alitalo, K. K., Daly, C., Thurston, G., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84871 · Cited by 245 · see citing works

Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels

Falcón, B. L., Hashizume, H., Koumoutsakos, P., Chou, J., BREADY, J. V., Coxon, A., Oliner, J. D., & McDonald, D. M. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090391 · Cited by 225 · see citing works

Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion

Coffelt, S. B., Chen, Y.-Y., Muthana, M., Welford, A. F., Tal, A. O., Scholz, A., Plate, K. H., Reiss, Y., Murdoch, C., De Palma, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002802 · Cited by 220 · see citing works

Cancer-Associated Fibroblasts Connect Metastasis-Promoting Communication in Colorectal Cancer

Tommelein, J., Verset, L., Boterberg, T., Demetter, P., Bracke, M., & Wever, O. D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00063 · Cited by 207 · see citing works

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

Goede, V., Coutelle, O., Neuneier, J., Reinacher-Schick, A. C., Schnell, R., Koslowsky, T. C., Weihrauch, M. R., Cremer, B., Kashkar, H., Odenthal, M., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605925 · Cited by 186 · see citing works

Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content

McCarty, M. F., Somcio, R., Stoeltzing, O., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31334 · Cited by 175 · see citing works

The Orphan Receptor Tie1 Controls Angiogenesis and Vascular Remodeling by Differentially Regulating Tie2 in Tip and Stalk Cells

Savant, S., Porta, S. L., Budnik, A., Busch, K., Hu, J., Tisch, N., Korn, C., Valls, A. F., Benest, A. V., Terhardt, D., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.024 · Cited by 172 · see citing works

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study

Van Cutsem, E., Martinelli, E., Cascinu, S., Sobrero, A., Banzi, M., Seitz, J.-F., Barone, C., Ychou, M., Peeters, M., Brenner, B., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0072 · Cited by 142 · see citing works

Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy

Bagri, A., Berry, L., Gunter, B., Singh, M., Kasman, I. M., Damico, L. A., Xiang, H., Schmidt, M., Fuh, G., Hollister, B. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3100 · Cited by 140 · see citing works

The Role of PDGFs and PDGFRs in Colorectal Cancer

Manzat-Saplacan, R. M., Bălăcescu, L., Gherman, C. D., Chira, R. I., Anca, C., Mircea, P. A., Lisencu, C. I., & Bălăcescu, O. (2017) · Mediators of Inflammation · doi:10.1155/2017/4708076 · Cited by 133 · see citing works

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

Adenis, A., de la Fouchardière, C., Paule, B., Burtin, P. C., Tougeron, D., Wallet, J., Dourthe, L.-M., Etienne, P.-L., Mineur, L., Clisant, S., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2440-9 · Cited by 129 · see citing works

Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma

Wu, R.-Y., Kong, P., Xia, L.-P., Huang, Y., Li, Z., Tang, Y.-Y., Chen, Y.-H., Li, X., Senthilkumar, R., Zhang, H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2840 · Cited by 116 · see citing works

Identification and characterization of RET fusions in advanced colorectal cancer

Rolle, A.-F. L., Klempner, S. J., Garrett, C. R., Seery, T. E., Sanford, E. M., Balasubramanian, S., Ross, J. S., Stephens, P. J., Miller, V. A., Ali, S. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4325 · Cited by 109 · see citing works

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected

Pietrantonio, F., Nicolantonio, F. D., Schrock, A. B., Lee, J., Morano, F., Fucà, G., Nikolinakos, P. G., Drilon, A. E. D. C., Hechtman, J. F., Christiansen, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy090 · Cited by 108 · see citing works

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial

Eisen, T. G., Joensuu, H., Nathan, P., Harper, P., Wojtukiewicz, M. Z., Nicholson, S., Bahl, A. K., Tomczak, P., Pyrhönen, S. O., Fife, K. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70364-9 · Cited by 105 · see citing works

Endothelial Tie1–mediated angiogenesis and vascular abnormalization promote tumor progression and metastasis

Porta, S. L., Roth, L., Singhal, M., Mogler, C., Spegg, C., Schieb, B., Qu, X., Adams, R. H., Baldwin, H. S., Savant, S., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94674 · Cited by 97 · see citing works

Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care

Grothey, A. F., George, S., Cutsem, E. V., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0059 · Cited by 80 · see citing works

Targeting RET-rearranged non-small-cell lung cancer: future prospects

Bronte, G., Ulivi, P., Verlicchi, A., Cravero, P., Delmonte, A., & Crinò, L. (2019) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s192830 · Cited by 74 · see citing works

Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study

Khan, K. H., Rata, M., Cunningham, D., Koh, D., Tunariu, N., Hahne, J. C., Vlachogiannis, G., Hedayat, S., Marchetti, S., Lampis, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2017-314178 · Cited by 72 · see citing works

Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).

Fukuoka, S., Hara, H., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2522 · Cited by 69 · see citing works

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib

Wong, A. L. A., Lim, J. S. J., Sinha, A. K., Gopinathan, A., Lim, R. S. C., Tan, C., Soh, I., Venkatesh, S. K., Titin, C., Sapari, N. S., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0405-4 · Cited by 67 · see citing works

Reprogramming Tumor Blood Vessels for Enhancing Immunotherapy

Schmittnaegel, M., & Palma, M. D. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.10.002 · Cited by 56 · see citing works

Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics

Sunakawa, Y., Furuse, J., Okusaka, T., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9953-8 · Cited by 55 · see citing works

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial

Argilés, G., Saunders, M. P., Rivera, F., Sobrero, A. F., Benson, A. B., Guillén‐Ponce, C., Cascinu, S., Cutsem, E. V., Macpherson, I. R., Strumberg, D., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.02.013 · Cited by 54 · see citing works

The Molecular Balance between Receptor Tyrosine Kinases Tie1 and Tie2 Is Dynamically Controlled by VEGF and TNFα and Regulates Angiopoietin Signalling

Singh, H., Hansen, T. M., Patel, N. R., & Brindle, N. P. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029319 · Cited by 50 · see citing works

Immunomodulation by regorafenib alone and in combination with anti PD1 antibody on murine models of colorectal cancer

Hoff, S., Grünewald, S., Röse, L., & Zopf, D. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx376.060 · Cited by 50 · see citing works

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer

Suenaga, M., Mashima, T., Kawata, N., Wakatsuki, T., Horiike, Y., Matsusaka, S., Dan, S., Shinozaki, E., Seimiya, H., Mizunuma, N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9187 · Cited by 46 · see citing works

Tie1: an orphan receptor provides context for angiopoietin-2/Tie2 signaling

Mueller, S. B., & Kontos, C. D. (2016) · Journal of Clinical Investigation · doi:10.1172/jci89963 · Cited by 45 · see citing works

KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers

Chen, E. C., Karl, T. A., Tomer Kalisky, C., Gupta, S. K., O'Brien, C. A., Longacre, T. A., van de Rijn, M., Quake, S. R., Clarke, M. F., & Rothenberg, M. E. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.042 · Cited by 43 · see citing works

The preclinical development of regorafenib for the treatment of colorectal cancer

Miura, K., Satoh, M., Kinouchi, M., et al. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.924923 · Cited by 40 · see citing works

Multicenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer

Sanoff, H. K., Goldberg, R. M., Ivanova, A., O’Reilly, S., Kasbari, S. S., Kim, R. D., McDermott, R., Moore, D. T., Zamboni, W. C., Grogan, W. M., et al. (2018) · Cancer · doi:10.1002/cncr.31552 · Cited by 38 · see citing works

Immunohistochemical Staining for c-Kit (CD117) Is a Rare Event in Human Colorectal Carcinoma

Reed, J., Ouban, A., Schickor, F. K., Muraca, P. J., Yeatman, T. J., & Coppola, D. (2002) · Clinical Colorectal Cancer · doi:10.3816/ccc.2002.n.018 · Cited by 37 · see citing works

Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor

Vandeputte, C., Kehagias, P., Housni, H. E., Ameye, L., Laes, J., Desmedt, C., Sotiriou, C. P., Deleporte, A., Puleo, F., Geboes, K. P., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24879 · Cited by 34 · see citing works

Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand–Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib

Suenaga, M., Schirripa, M., Cao, S., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.02.010 · Cited by 32 · see citing works

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients

Giampieri, R., Salvatore, L., Prete, M. D., Prochilo, T., D’Anzeo, M., Loretelli, C., Loupakis, F., Aprile, G., Maccaroni, E., Andrikou, K., et al. (2016) · Scientific Reports · doi:10.1038/srep25195 · Cited by 30 · see citing works

Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial

Teufel, M., Schwenke, S., Seidel, H., Beckmann, G., Reischl, J., Vonk, R., Lenz, H.-J., Tabernero, J., Siena, S., Grothey, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3558 · Cited by 26 · see citing works

Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene

Oliveira, D. M., Grillone, K., Mignogna, C., Falco, V. D., Laudanna, C., Biamonte, F., Locane, R., Corcione, F., Fabozzi, M., Sacco, R., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0746-y · Cited by 26 · see citing works

Multiple Effects of Angiopoietin-2 Blockade on Tumors

Lewis, C. E., & Ferrara, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.016 · Cited by 23 · see citing works

c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer

Shah, Y. M., & BRINK, G. R. V. D. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.027 · Cited by 19 · see citing works

Biological and Molecular Effects of Small Molecule Kinase Inhibitors on Low-Passage Human Colorectal Cancer Cell Lines

Lange, F., Franz, B., Maletzki, C., et al. (2014) · BioMed Research International · doi:10.1155/2014/568693 · Cited by 18 · see citing works

Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Final results of the prospective multicentre non-interventional RECORA study.

Schulz, H., Janßen, J., Strauss, U. P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.748 · Cited by 17 · see citing works

c-Kit Proto-Oncogene Product Is Rarely Detected in Colorectal Adenocarcinoma

Yorke, R. F., Chirala, M., & Younes, M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.99.213 · Cited by 16 · see citing works

Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: A clinician’s perspective

Clarke, J. M., Hurwitz, H. I., & Rangwala, F. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.07.001 · Cited by 15 · see citing works

Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC).

Komatsu, Y., Muro, K., Yamaguchi, K., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.721 · Cited by 14 · see citing works

Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)

Alfonso, P. G., Benavides, M., Falcó, E., Martín, A. J. M., Gómez, A., Sastre, J., Rivera, F., Montagut, C. O., Salgado, M., López-Ladrón, A., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0316 · Cited by 12 · see citing works

Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Interim results of the prospective multicentre noninterventional RECORA study.

Schulz, H., Janßen, J., Strauss, U. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.769 · Cited by 10 · see citing works

Analysis of plasma protein biomarkers from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC).

Teufel, M., Kalmus, J., Rutstein, M. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.672 · Cited by 9 · see citing works

PD-003 Analysis of single-nucleotide polymorphisms (SNPs) in the phase 3 CORRECT trial of regorafenib vs placebo in patients with metastatic colorectal cancer (mCRC)

Lambrechts, D., Köchert, K., Schulz, A. L., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw200.03 · Cited by 8 · see citing works

Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC): Interim analysis from the prospective, observational CORRELATE study

Juan, M. O., Öhler, L., Scheithauer, W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx263.024 · Cited by 8 · see citing works

Exploratory analysis of baseline microsatellite instability (MSI) status in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) or placebo in the phase 3 CORRECT trial

Köchert, K., Beckmann, G., & Teufel, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx393.060 · Cited by 7 · see citing works

Outcomes by tumor location in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): Final analysis from the prospective, observational CORRELATE study.

Ducreux, M. P., Pétersen, L. N., Öhler, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.539 · Cited by 6 · see citing works

Matrix metalloproteinase-related gene polymorphisms to predict efficacy of regorafenib in patients with metastatic colorectal cancer.

Suenaga, M., Schirripa, M., Cao, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.692 · Cited by 3 · see citing works

Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer

Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130 · see citing works

Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review

Li, Y., Chen, X., Li, W., Ye, Y., Du, X., Sun, S., Liu, L., & Zhang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684309 · Cited by 24 · see citing works

Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging

Liu, S., Du, Y., Ma, H., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.037 · Cited by 27 · see citing works

Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment

Ogasawara, S., Chiba, T., Ooka, Y., Suzuki, E., Maeda, T., Yokoyama, M., Wakamatsu, T., Inoue, M., Saito, T., Kobayashi, K., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0507-3 · Cited by 66 · see citing works

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

Finn, R. S., Merle, P., Granito, A., Huang, Y., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Gerolami, R., Caparello, C., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.04.010 · Cited by 347 · see citing works

Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer

Singal, A. K., & Ravi, S. (2014) · Core evidence · doi:10.2147/ce.s48626 · Cited by 30 · see citing works

Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma

Yoo, C., Park, J., Kim, Y. J., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0707-5 · Cited by 50 · see citing works